SVB Leerink Downgrades Epizyme (EPZM) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts EPZM Hot Sheet
Price: $1.47 --0%
Rating Summary:
8 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Rating Summary:
8 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 90
Join SI Premium – FREE
SVB Leerink analyst Andrew Berens downgraded Epizyme (NASDAQ: EPZM) from Outperform to Market Perform with a price target of $18.00 (from $16.00).
For an analyst ratings summary and ratings history on Epizyme click here. For more ratings news on Epizyme click here.
Shares of Epizyme closed at $26.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Albertsons Companies Inc. (ACI) to Underperform
- Goldman Sachs Downgrades China Resources Beverage (2460:HK) to Sell
- Freedom Broker Downgrades Taylor Devices, Inc. (TAYD) to Hold
Create E-mail Alert Related Categories
DowngradesRelated Entities
Andrew BerensSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
